SCHEMBL1068871

SCHEMBL1068871

CCOC(=O)[C@@H](N)Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.48
GAA P10253 2/20 0.48
LMNA P02545 3/20 0.47
KCNJ1 P48048 1/20 0.47
KCNH2 Q12809 1/20 0.47
MMP2 P08253 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
DPP4 P27487 1/20 0.46
DPP8 Q6V1X1 1/20 0.46
DPP9 Q86TI2 1/20 0.46
DPP7 Q9UHL4 1/20 0.46
RAB9A P51151 1/20 0.45
IDO1 P14902 1/20 0.45
LOXL2 Q9Y4K0 1/20 0.45
MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1859542 1.00 MAPT (0.50) MAPTCRHBPCRHR2L3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL1859934 0.99 ALDH1A1 (0.50) MAPTCRHBPCRHR2L3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL1859938 0.99 ALDH1A1 (0.50) MAPTCRHBPCRHR2L3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL17707255 0.99 ALDH1A1 (0.50) MAPTCRHBPCRHR2L3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL6131679 0.97 MAPT (0.48) MAPTCRHBPCRHR2L3MBTL1ALDH1A1
SCHEMBL4367409 0.87 ALDH1A1 (0.62) ALDH1A1GAALMNAMMP2SMN1; SMN2
SCHEMBL3317059 0.87 ALDH1A1 (0.62) ALDH1A1GAALMNAMMP2SMN1; SMN2
SCHEMBL240405 0.87 ALDH1A1 (0.62) ALDH1A1GAALMNAMMP2SMN1; SMN2
SCHEMBL11651148 0.86 MMP2 (0.49) MAPTALDH1A1LMNAMMP2DPP4
SCHEMBL28998132 0.86 ALDH1A1 (0.47) MAPTCRHBPCRHR2L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081503-B1 A PROCESS FOR THE SYNTHESIS OF MELPHALAN INDENA SPA (IT) 2025-07-30 EP disclosed
US-12077484-B2 Process for the synthesis of melphalan INDENA S.P.A. (IT) 2024-09-03 US disclosed
CN-114845991-B Method for synthesizing melphalan 意迪那有限公司 2024-05-07 CN disclosed
EP-3015488-B1 PRODUCTION METHOD FOR POLYAMINO ACID TAKEDA PHARMACEUTICALS CO (JP) 2024-03-06 EP disclosed
US-11787761-B2 Process for the synthesis of Melphalan INDENA S.P.A. (IT) 2023-10-17 US disclosed
US-20230286901-A1 PROCESS FOR THE SYNTHESIS OF MELPHALAN INDENA S.P.A. (IT) 2023-09-14 US disclosed
US-20230094970-A1 A PROCESS FOR THE SYNTHESIS OF MELPHALAN INDENA S.P.A. (IT) 2023-03-30 US disclosed
EP-4081503-A1 A PROCESS FOR THE SYNTHESIS OF MELPHALAN Indena S.p.A. (IT) 2022-11-02 EP disclosed
CN-114845991-A Method for synthesizing melphalan 因德纳有限公司 2022-08-02 CN disclosed
CN-114315618-A Preparation method of synthetic melphalan 浙江恒腾福生物科技集团有限公司 2022-04-12 CN disclosed
EP-1117657-A1 PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 2001-07-25 EP disclosed
EP-1073434-A1 CCR-3 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-02-07 EP disclosed
WO-2000043413-A2 PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2000-07-27 WO disclosed
WO-2000018759-A1 PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 2000-04-06 WO disclosed
WO-1999055330-A1 CCR-3 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-11-04 WO disclosed
EP-0879227-A1 TYROSIN-DERIVATE AS ALPHA-V-INTEGRIN INHIBITORS MERCK PATENT GmbH (DE) 1998-11-25 EP disclosed
US-5677322-A THERAPY FOR AGING, DIABETES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-10-14 US disclosed
WO-1997023451-A1 TYROSIN-DERIVATE AS ALPHA-V-INTEGRIN INHIBITORS MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1997-07-03 WO disclosed
EP-0638075-A1 THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-02-15 EP disclosed
WO-1994019335-A1 THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230094970-A1 A PROCESS FOR THE SYNTHESIS OF MELPHALAN PAH, IL4I1, TYR MAPT 4067/4885CRHBP 3358/4885CRHR2 3283/4885
US-12077484-B2 Process for the synthesis of melphalan PAH, TYR, IL4I1 MAPT 3868/4885CRHBP 3254/4885CRHR2 2991/4885
US-11787761-B2 Process for the synthesis of Melphalan PAH, TYR, MARS1 MAPT 3926/4885CRHBP 3285/4885CRHR2 2890/4885
US-20230286901-A1 PROCESS FOR THE SYNTHESIS OF MELPHALAN PAH, TYR, IL4I1 MAPT 3868/4885CRHBP 3254/4885CRHR2 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.